Gilead Sciences
Company ● Covered in 1 story + Follow ✴ AI Graph
This profile is built automatically from TLDRocket coverage.
Signals
0 stories (-100%)
Media momentum
As of 24 Sep 2026 · Visible stories in the last 30 days, compared with the 30 days before.
1 source
Source diversity
As of 24 Sep 2026 · Distinct publications behind this entity's visible coverage.
—
Release activity
As of 24 Sep 2026 · Model, product and open-source release events in the last 90 days whose coverage involves this entity.
—
Funding signals
As of 24 Sep 2026 · Funding and acquisition events in the last 90 days whose coverage involves this entity.
Aug 2026
Coverage span
As of 24 Sep 2026 · First to most recent month of TLDRocket coverage of this entity.
Management
updated 8 Sep 2026- Daniel O’day Chairman and Chief Executive Officer
- Andrew Dickinson Chief Financial Officer
- Medi Yanuarto President
- Anonymous Chief Commercial Officer
- Flavius Martin Executive Vice President, Research
- Stacey Ma EVP, Head of Pharmaceutical Development and Manufacturing
- Dietmar Berger Chief Medical Officer
- Amy Klug VP, Chief of Staff, Corporate Strategy & Projects, CEO Office
- Anna Berg Asberg SVP IT & Global CIO
- Janay Jones Executive Director
- Jane Stafford President, Gilead Foundation
- Mark Hill Senior Vice President & CIO
+ 12 more tracked
Latest developments
2026
Relationships
Products & technology
- Deploys Graph neural networks · 1 source
- Integrated with Neo4j · 1 source